Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Erigeron Canadensis
Brand Name
Erigeron Canadensis
Generic Name
Erigeron Canadensis
Active Ingredient
Erigeron CanadensisCategory
Non-Standardized Food Allergenic Extract [EPC]
Variants
9
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 1 [hp_Q]/1 | PELLET | ORAL | 37662-0710 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-0708 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-0709 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Erigeron Canadensis, you must consult a qualified healthcare professional.
| 30 [hp_C]/1 | PELLET | ORAL | 37662-0705 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-0706 |
| 200 [hp_C]/1 | PELLET | ORAL | 37662-0707 |
| 12 [hp_C]/1 | PELLET | ORAL | 37662-0704 |
| 30 [hp_C]/30[hp_C] | PELLET | ORAL | 0220-1900 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-0703 |
Detailed information about Erigeron Canadensis
Erigeron Canadensis is a non-standardized plant allergenic extract used primarily for the diagnosis and treatment of Type I hypersensitivity to Horseweed pollen. It belongs to the class of Non-Standardized Plant Allergenic Extracts [EPC].
Dosage for Erigeron Canadensis is highly individualized and must be determined by an allergist based on the patient's sensitivity and clinical history. There is no 'standard' dose due to the non-standardized nature of the extract.
Immunotherapy consists of two distinct phases:
Erigeron Canadensis extract is used in children, but the starting dose may be more conservative depending on the child's age and the severity of their allergic symptoms. The safety and efficacy in children under the age of 5 have not been extensively established, and healthcare providers must weigh the benefits against the risk of systemic reactions in young children who may not be able to communicate early symptoms of anaphylaxis.
No specific dosage adjustments are required for patients with renal impairment, as the allergenic proteins are not cleared by the kidneys in a manner that would lead to toxicity.
No dosage adjustments are necessary for patients with hepatic impairment.
Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk-benefit ratio must be carefully assessed because the use of epinephrine (the primary treatment for a severe reaction) may be more hazardous in this population.
Erigeron Canadensis extract is never self-administered. It must be administered by a trained healthcare professional in a medical facility.
If an immunotherapy dose is missed, the next dose may need to be reduced depending on how much time has passed since the last injection.
An 'overdose' in the context of allergenic extracts usually refers to an injection of a concentration higher than the patient's current tolerance level. This significantly increases the risk of a systemic reaction or anaphylaxis.
Emergency Measures: Immediate administration of intramuscular epinephrine, followed by antihistamines, corticosteroids, and emergency transport to a hospital if necessary.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing immunotherapy with Erigeron Canadensis will experience local reactions at the site of injection. These are generally not dangerous but can be uncomfortable.
Erigeron Canadensis allergenic extract is intended for use only by licensed medical professionals. It is a potent biological agent that can induce a severe immune response in sensitive individuals. Patients should be in stable health at the time of their injection; if you have a fever, respiratory infection, or an active asthma flare-up, your injection should be postponed.
No specific unique black box warning exists for Erigeron Canadensis alone, but it falls under the Class-Wide Warning for Allergenic Extracts: "This product can cause severe systemic reactions, including anaphylaxis, which may be fatal. It must be administered in a facility equipped with emergency supplies, including epinephrine, and by staff trained in emergency resuscitation."
Erigeron Canadensis must NEVER be used in the following circumstances:
Pregnancy Category: C (as per traditional FDA categories).
There is no evidence that allergenic proteins from Erigeron Canadensis pass into breast milk in any significant quantity. Immunotherapy is generally considered safe for breastfeeding mothers. The mother's immune response (IgG4 production) may even have a theoretical protective effect, though this is not a primary reason for treatment.
Erigeron Canadensis extract acts as an immunomodulator. In the diagnostic phase, it acts as an antigen that bridges IgE molecules on mast cells. In the therapeutic phase, it works by inducing a state of 'immunological desensitization.' This involves:
Common questions about Erigeron Canadensis
Erigeron Canadensis, or Horseweed extract, is primarily used for the diagnosis and treatment of seasonal allergies. In a clinical setting, it is used in skin prick tests to identify if a patient is allergic to this specific plant's pollen. If an allergy is confirmed and symptoms are severe, the extract is used in 'allergy shots' (immunotherapy) to help the body build a tolerance. This treatment aims to reduce symptoms like sneezing, itchy eyes, and asthma flares during the late summer and fall. It is only administered by specialists in a controlled medical environment.
The most common side effects are localized reactions at the site of the injection or skin test. These include redness, itching, and a small amount of swelling (a wheal) that typically resolves within a few hours. Some patients may also experience a 'large local reaction' where the swelling exceeds two inches in diameter. While these are uncomfortable, they are generally not dangerous. However, they must be reported to the doctor before the next dose is given to ensure the dosage is adjusted correctly.
It is generally recommended to avoid alcohol for several hours after receiving an Erigeron Canadensis injection. Alcohol can cause blood vessels to dilate, which might increase the rate at which the allergen is absorbed into your bloodstream, potentially increasing the risk of a systemic reaction. Furthermore, alcohol can mask the early symptoms of an allergic reaction, such as feeling flushed or dizzy. To ensure maximum safety during the critical hours following an immunotherapy dose, it is best to remain sober. Always consult your allergist for their specific policy regarding lifestyle restrictions.
The safety of Erigeron Canadensis during pregnancy depends on whether you are just starting treatment or are already on a stable dose. Doctors typically do not start new immunotherapy during pregnancy because of the risk of anaphylaxis, which could be harmful to the developing fetus. However, if you are already on a maintenance dose and are tolerating it well, your doctor may choose to continue the injections. The dose is usually not increased while you are pregnant to minimize risks. A thorough discussion with your allergist and obstetrician is necessary to make this decision.
When used for diagnosis, Erigeron Canadensis works within 15 to 20 minutes to produce a skin reaction. For therapeutic immunotherapy, the process is much slower and requires patience. Most patients begin to notice a reduction in their allergy symptoms about 3 to 6 months after they reach their 'maintenance dose.' Significant and long-lasting relief usually requires staying on the treatment for 3 to 5 years. If no improvement is seen after one full year of maintenance therapy, your doctor may re-evaluate the treatment plan.
Yes, you can stop Erigeron Canadensis injections suddenly without experiencing a 'withdrawal' in the traditional sense, as it is not an addictive medication. However, stopping the treatment before the recommended 3-to-5-year course is finished will likely result in the return of your allergy symptoms over time. The immune system requires consistent exposure to the allergen to maintain its tolerance. If you need to stop due to side effects or life changes, discuss a tapering or alternative plan with your allergist. Do not expect the desensitization to last if the course is incomplete.
If you miss a dose of your Erigeron Canadensis immunotherapy, contact your allergist's office immediately to reschedule. The procedure for a missed dose depends on how long it has been since your last injection. If only a few days have passed, you may continue with the scheduled dose. However, if several weeks have passed, your doctor will likely need to reduce the dose for your next injection to ensure your safety. This prevents a sudden 'jump' in allergen exposure that your immune system might not be prepared for, reducing the risk of a reaction.
There is no clinical evidence to suggest that Erigeron Canadensis allergenic extract causes weight gain. The extract consists of natural proteins and glycoproteins administered in very small quantities subcutaneously. It does not contain hormones, steroids, or calories that would affect metabolic rate or fat storage. If you experience weight changes while on immunotherapy, they are likely due to other factors, such as other medications (like oral steroids for asthma) or changes in lifestyle. Always discuss weight concerns with your primary care physician.
Erigeron Canadensis can be taken with most medications, but there are critical exceptions. You must inform your doctor if you are taking beta-blockers, which are often used for high blood pressure or heart conditions, as they can make allergic reactions harder to treat. Other medications like ACE inhibitors and MAO inhibitors may also require special caution. Antihistamines should be avoided before skin testing because they can block the reaction and lead to a false negative. Always provide a full list of your medications to your allergist before starting treatment.
Erigeron Canadensis is a biological product rather than a chemically synthesized drug, so the term 'generic' does not apply in the same way it does to tablets like ibuprofen. However, various manufacturers produce Erigeron Canadensis extracts. While they all contain the same basic pollen proteins, they are 'non-standardized,' meaning the potency can vary between different brands or even different batches. For this reason, allergists prefer not to switch between different manufacturers' extracts once a patient has started their immunotherapy build-up, as it could increase the risk of a reaction.
> Warning: Stop taking Erigeron Canadensis and call your doctor immediately if you experience any of these symptoms of a systemic reaction.
There are no known long-term 'toxic' side effects associated with the chronic use of allergenic extracts like Erigeron Canadensis. Unlike many pharmaceuticals, these are biological proteins that do not accumulate in organs. The primary long-term consideration is the successful modification of the immune system. However, if a patient develops a new autoimmune condition, the continuation of immunotherapy should be re-evaluated by a specialist.
While Erigeron Canadensis extracts may not always carry a formal 'Black Box' on every individual vial label, the FDA requires a standardized warning for the entire class of allergenic extracts regarding the risk of severe systemic reactions.
Report any unusual symptoms to your healthcare provider immediately.
Erigeron Canadensis does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.
While there is no direct chemical interaction between alcohol and Erigeron Canadensis, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption or worsen the symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours after an injection.
Immunotherapy is typically a 3-to-5-year commitment. Stopping prematurely may result in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the desensitization benefits will gradually diminish if the maintenance phase is not completed.
> Important: Discuss all your medical conditions with your healthcare provider before starting Erigeron Canadensis.
There are no known direct food interactions with Erigeron Canadensis extract. However, patients with a 'weed-food' allergy syndrome (pollen-food allergy syndrome) may experience cross-reactivity. For example, some people allergic to weeds in the Asteraceae family may react to chamomile tea or certain sunflower products. Discussing these sensitivities with your doctor is vital.
For each major interaction, the mechanism involves either the interference with the body's response to the allergen or the interference with the emergency medications used to treat a reaction. The management strategy is usually the discontinuation of the interfering drug or a very careful risk-benefit analysis by the specialist.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Conditions requiring careful risk-benefit analysis include:
Erigeron Canadensis belongs to the Asteraceae family. Patients may show cross-sensitivity to other 'weeds' such as:
A positive skin test for Erigeron Canadensis often correlates with sensitivities to these other botanical relatives.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Erigeron Canadensis.
Immunotherapy with Erigeron Canadensis is effective in children, particularly for preventing the progression of allergic rhinitis to asthma (the 'allergic march').
Patients over age 65 may have a higher prevalence of cardiovascular disease, which increases the risk associated with immunotherapy.
No dosage adjustment is required for patients with kidney disease. The proteins in the extract are processed by the immune system and proteases, not by renal filtration.
No dosage adjustment is required for patients with liver disease. The extract does not undergo significant hepatic metabolism via the cytochrome P450 system.
> Important: Special populations require individualized medical assessment by an allergy specialist.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous administration) |
| Protein Binding | N/A (Proteins are processed by APCs) |
| Half-life | Varies by protein component (hours to days) |
| Tmax | 15–30 minutes (systemic absorption of small amounts) |
| Metabolism | Proteolytic degradation in lysosomes |
| Excretion | Minimal renal excretion of peptide fragments |
Erigeron Canadensis is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic category of Allergen Immunotherapy Agents. Related medications include extracts for Ragweed (Ambrosia), Timothy Grass (Phleum pratense), and Oak (Quercus).